<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Care Res (Hoboken)</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Care Res (Hoboken)</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Arthritis care &amp; research</journal-title></journal-title-group><issn pub-type="ppub">2151-464X</issn><issn pub-type="epub">2151-4658</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10843294</article-id><article-id pub-id-type="pmcid-ver">PMC10843294.319</article-id><article-id pub-id-type="pmcaid">10843294</article-id><article-id pub-id-type="pmcaiid">10843294</article-id><article-id pub-id-type="manuscript-id">NIHMS1937397</article-id><article-id pub-id-type="pmid">37605840</article-id><article-id pub-id-type="doi">10.1002/acr.25219</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1937397</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1937397</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Incidence rate and factors associated with fractures among Medicare beneficiaries with ankylosing spondylitis in the United States</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Stovall</surname><given-names initials="R">Rachael</given-names></name><degrees>MD MAS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kersey</surname><given-names initials="E">Emma</given-names></name><degrees>MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jing</given-names></name><degrees>MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baker</surname><given-names initials="R">Rahaf</given-names></name><degrees>MD MPH</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anastasiou</surname><given-names initials="C">Christine</given-names></name><degrees>MD MAS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Palmowski</surname><given-names initials="A">Andriko</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schmajuk</surname><given-names initials="G">Gabriela</given-names></name><degrees>MD MS</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gensler</surname><given-names initials="L">Lianne</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yazdany</surname><given-names initials="J">Jinoos</given-names></name><degrees>MD MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Rheumatology, University of California San Francisco (UCSF), San Francisco, CA</aff><aff id="A2"><label>2</label>Alameda Health System, Oakland, CA</aff><aff id="A3"><label>3</label>Department of Rheumatology and Clinical Immunology, Charit&#233; &#8211; Universit&#228;tsmedizin Berlin</aff><aff id="A4"><label>4</label>Section for Biostatistics and Evidence-Based Research, the Parker Institute, University of Copenhagen, Copenhagen, Denmark</aff><aff id="A5"><label>5</label>San Francisco VA Healthcare System</aff><aff id="A6"><label>6</label>UCSF Institute for Health Policy Research</aff><author-notes><corresp id="CR1">Corresponding author: Rachael Stovall, MD MAS, 513 Parnassus Ave # 500, San Francisco, CA 94143-2205, <email>restovall@gmail.com</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P43">Declarations of Interest</p><p id="P44">R. Stovall, None; E. Kersey, None; J. Li, None; R. Baker, None; C. Anastasiou, None; A. Palmowski, None; G. Schmajuk, None; L. Gensler, Novartis, Pfizer Inc, UCB Pharma, AbbVie, Eli Lilly, Janssen, Gilead, Moonlake; J. Yazdany, AstraZeneca, Gilead, Bristol-Myers Squibb(BMS), Aurinia, Pfizer.</p></fn></author-notes><pub-date pub-type="ppub"><month>2</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2023</year></pub-date><volume>76</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">455061</issue-id><fpage>265</fpage><lpage>273</lpage><pub-history><event event-type="nihms-submitted"><date><day>13</day><month>10</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-01 15:25:33.110"><day>01</day><month>02</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1937397.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P1">We evaluated the incidence rate and factors associated with fractures among adults with ankylosing spondylitis (AS).</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We performed a retrospective cohort study with data from the Rheumatology Informatics System for Effectiveness (RISE) registry linked to Medicare claims from 2016&#8211;2018. Patients were required to have two AS ICD codes, &#8805;30 days apart, and a subsequent Medicare claim. Then, one year of baseline characteristics were included, after which patients were observed for fractures. First, we calculated the incidence rate of fractures. Second, we constructed logistic regression models to identify factors associated with fracture, including age, sex, race/ethnicity, body mass index, Medicare/Medicaid dual-eligibility, area deprivation index, Charlson comorbidity index, smoking status, osteoporosis, historical fracture, and use of osteoporosis treatment, glucocorticoids, and opioids.</p></sec><sec id="S3"><title>Results:</title><p id="P3">We identified 1,426 adults with prevalent AS. Mean (SD) age was 69.4 years (9.8), 44.3% were female, and 77.3% were non-Hispanic White. Fractures occurred in 197 adults with AS. The overall incidence rate of fractures was 76.7 (95% CI 66.4&#8211;88.6) per 1,000 person-years. Older age (OR 2.8, 95% CI 1.39&#8211;5.65), historical fracture (OR 5.24, 95% CI 3.44&#8211;7.99), and use of &gt;30 mg morphine equivalent (OR 1.86, 95% CI 1.08&#8211;3.19) conferred increased odds of fracture.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">In this large sample of Medicare beneficiaries with AS, increasing age, historical fracture, and use of opioids had a higher odds of fracture. Men and women were equally likely to have a fracture. Because opioid use was associated with fracture in AS, this high-risk population should be considered for interventions to mitigate risk.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>